Chest
Clinical InvestigationsJournal ArticleLong-term Survival and Toxicity in Small Cell Lung Cancer: Expanded Southwest Oncology Group Experience
Section snippets
Patients and Methods
The formation of the SCLC database of 2,501 eligible patients entered on consecutive SWOG trials from 1976 to 1986 is summarized elsewhere.9 For all patients, standard evaluation and staging criteria for the time period were employed. Radionuclide bone scans were required for all patients. Radionuclide brain and liver scans were required until 1982, and computed tomographic (CT) brain and body scans were required thereafter. Contralateral supraclavicular nodes and isolated pleural effusion were
Logistic Regression and Long-term Survival Analyses for LD
The long-term survival percentages and results of the logistic regression analyses for the 1,363 eligible patients enrolled on SWOG LD studies are shown in Tables 2 and 3, respectively. Study 8269 (concurrent chemoradiotherapy) and superior 2- and 5-year survival compared with the three preceding trials.10 In the first logistic regression model (Table 3), which analyzed predictors of 5-year survival, all patients had to have a chance of survival for at least 5 years. Thus, the majority of
Discussion
This analysis of second-generation SCLC trials of the SWOG documented improvement in long-term survival without subsequent recurrence or persistent toxicity in the majority of patients with LD and in a few patients with ED. Overall, we observed that 24 percent of patients with LD survived ≥2 years and 7 percent survived ≥5 years. In the ED population, 23 percent lived ≥1 year, 4 percent lived ≥2 years, and 1 percent lived ≥5 years. Our first group-wide study of 373 patients that opened in 1974
Appendix
The following served as principal investigators for the SWOG studies analyzed in this manuscript: J. Blasko, G. Friess, P. Giri, B. Griffin, G. Goodman, B. Hom, L. Janaki, M. Kies, E Kim, J. D. McCracken, T. Miller, J. Mira, R. O'Bryan, C. Taylor, S. Taylor, and S. Williamson.
ACKNOWLEDGMENTS
We wish to thank the many SWOG members for contribution of patients to these trials, Gloria Chambers for assistance in preparing the database, Richard Fisher, M. D., for helpful comments, and Caroline Fazio for her preparation of the manuscript.
References (23)
- et al.
Long-term survival and toxicity in small cell lung cancer: a Southwest Oncology Group study
Am J Med
(1984) - et al.
Therapy of small cell lung cancer: a perspective on two decades of clinical research
Semin Oncol
(1988) - et al.
Ten-year survival of patients with smallcell lung cancer treated with combination chemotherapy with or without irradiation
J Clin Oncol
(1990) - et al.
Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 10-year survivors
J Clin Oncol
(1990) - et al.
Is prophylactic cranial irradiation indicated in small-cell lung cancer
J Clin Oncol
(1990) - et al.
Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: the Toronto experience
J Clin Oncol
(1990) - et al.
Dombernowsky P Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer
J Clin Oncol
(1986) - et al.
Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study
Ann Intern Med
(1978) - et al.
Determinants of improved outcome in small cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group Data base
J Clin Oncol
(1990) - et al.
Concurrent chemotherapy/radiotherapy for limited small cell lung carcinoma
J Clin Oncol
(1990)
Cited by (92)
Small Cell Lung Cancer
2021, Encyclopedia of Respiratory Medicine, Second EditionCancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer
2019, Abeloff’s Clinical OncologyProphylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: Outcomes at a Comprehensive Cancer Centre
2018, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Having a complete response to chemotherapy did not appear to impact either outcome in our analysis. Of note, a higher ECOG score was identified as a poor prognostic factor, which is consistent with several published studies (16-19). Most importantly however, PCI remained beneficial and was the strongest independent factor for both survival and in delaying brain metastasis development while accounting for these possibly confounding variables.
Percutaneous Thermal Ablation for Small-Cell Lung Cancer: Initial Experience with Ten Tumors in Nine Patients
2016, Journal of Vascular and Interventional RadiologyPrognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy
2016, Clinical Lung CancerCitation Excerpt :In first-line setting, several prognostic factors were reported: stage (LD or ED), sex, age, PS, lactate dehydrogenase level, alkaline phosphatase, white blood cell count, and the presence or absence of liver metastases.15-17 In the second-line setting, PS at recurrence, disease extent (LD or ED), and duration of response to first-line chemotherapy were reported to be significant prognostic factors in patients with recurrent SCLC.18,19 However, little is known about prognostic factors in the third-line setting.
Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy
2015, Cancer LettersCitation Excerpt :Recurrent tumors are than often resistant or has only a mild response to further treatment [5,6]. Only 10% of patients with advanced tumors survive longer than 2 years, leading to a five-year survival rate of only 3%–7% [7–9]. Therefore, clues to a more effective treatment for primary SCLC and its metastases are of utmost interest.
This investigation was supported in part by DHS Cooperative Agreement grants CA-46282, CA-37429, CA-20319, and CA-32102 awarded by the National Cancer Institute, DHHS. The principal investigators for the studies analyzed are acknowledged in the appendix.
Manuscript received September 19; revision accepted November 6.